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Abstract
Introduction: There is a lack of prospective studies comparing Roux-en-Y gastric bypass (RYGB) and one-
anastomosis gastric bypass (OAGB). Also, the effects of bariatric surgery and weight loss need a deeper
understanding through metabolic studies. We describe the trial protocol and interim analysis of a prospective
randomized controlled study comparing RYGB and OAGB: the RYSA trial.
Materials and methods: In total, 120 bariatric patients will be randomized between RYGB and OAGB in two
academic centers. All patients will be followed up for 10 years with analysis and measurements of weight,
comorbidities, blood tests, body composition and questionnaires. Extensive metabolic analyses (mixed meal tests,
energy expenditure, biopsies of muscle and subcutaneous fat, urine, saliva and fecal samples) will be carried out in
the Obesity Research Unit, University of Helsinki, for all patients treated at the Helsinki University Hospital (80
patients) at baseline, 6 months and 12 months. Bile reflux will be studied for the OAGB group at the Helsinki
University Hospital at 6 months with gastroscopy and scintigraphy.
Results: At an interim analysis at 3 months (half-way) through recruitment (30 RYGB and 30 OAGB patients) there
have been no deaths and no intensive care unit admittances. One patient in both groups required additional
gastroscopy, with anastomosis dilatation in the RYGB group but with no additional intervention in the OAGB group.
Conclusion: The trial can be safely carried out. Recruitment is estimated to be complete by the end of 2019.
Trial registration: Clinical Trials Identifier NCT02882685. Registered on August 30th 2016.
Keywords: Obesity, Bariatric surgery, Metabolic surgery, Roux-en-Y gastric bypass, One-anastomosis gastric bypass
Introduction
Surgery is the most effective treatment for morbid obes-
ity, and gastric bypass has been considered a gold stand-
ard [1, 2]. Currently there are several viable options for
performing a gastric bypass. Roux-en-Y gastric bypass
(RYGB) has been modified from the bypass method pub-
lished by Mason and Ito in the 1960s [3]. The hallmarks of
RYGB are a small gastric pouch anastomosed to an alimen-
tary limb and a separate biliopancreatic (BP) limb [4]. In
2001 Rutledge published a technique called mini-gastric by-
pass (MGB; later termed one-anastomosis gastric bypass
(OAGB) or single-anastomosis gastric bypass (SAGB)) with
a longer tubular-shaped pouch and a longer BP limb anas-
tomosed directly into the distal end of the gastric pouch
[5]. Since then, and according to the International Feder-
ation for the Surgery of Obesity and Metabolic Disorders
2018 statement on MGB/OAGB/SAGB procedures, a pre-
ferred term for all bypasses with a long gastric pouch and a
long BP limb should be OAGB [6].
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RYGB and OAGB have both shown excellent weight-
loss results in many cohort series and prospective trials
[7–9]. However, to our knowledge only two prospective
randomized controlled trials comparing RYGB and
OAGB have been published [10, 11]. It has been stated
that OAGB would be at least as effective, faster to per-
form and less prone to complications such as internal
herniations compared to RYGB [12]. On the other hand,
it has been suggested that OAGB can cause bile reflux, a
potential risk for premalignant Barrett’s metaplasia of
the esophagus. OAGB has been proposed to have a more
favorable effect on type 2 diabetes mellitus (T2DM) but
might be more prone to nutritional deficiencies [6, 11].
The BP limb is usually longer in OAGB compared to
RYGB, which most likely affects T2DM remission, but
limb lengths have not been standardized in either pro-
cedure. Overall, there are a lot of unanswered questions
when comparing RYGB and OAGB. A recent meta-
analysis on this subject concluded that a larger sample
size and multicenter randomized controlled trials are
needed to compare the effectiveness and safety between
these procedures [13].
Bariatric surgery induces changes in the entire body in-
cluding body composition, bile acid metabolism, energy
expenditure, cellular metabolism, gut microbiota, chronic
stress, vitamin and electrolyte homeostasis, glucose toler-
ance and lipid metabolism, as well as eating behavior,
physical activity, self-image, social relationships and qual-
ity of life. The mechanisms of these changes are not fully
understood, and neither are the differences in the under-
lying mechanisms of RYGB and OAGB. A comprehensive
approach to obesity management is needed in order to be
able to tailor a treatment for each patient.
Our objective is to compare outcomes of RYGB and
OAGB procedures and to study comprehensively all
changes in obesity-related conditions in a prospective
study where we randomize between RYGB and OAGB.
Here we describe the trial protocol for a randomized
controlled trial, the Roux-en-Y Gastric Bypass vs Single-
Anastomosis Gastric Bypass (RYSA) trial, with an
interim analysis regarding safety and trial progression.
Materials and methods
Aims of the study
The primary outcome is weight loss 2 years after the op-
eration. Weight loss is measured as percentage excess
weight loss (%EWL) and percentage total weight loss
(%TWL). %EWL is calculated as a percentage of lost ex-
cess weight since the preoperative visit compared to an
ideal weight with a body mass index (BMI) of 25 kg/m2.
Weight loss will also be analyzed as a grouping variable
according to different categories of weight loss to com-
pare responders and nonresponders to bariatric surgery.
For EWL% we use the categories 0–24.99%, 25–49.99%,
50–74.99% and ≥75%, and for TWL% we use the cat-
egories <10%, 10–19.99%, 20–29.99%, 30–39.99%, ≥40%
to determine participants with different amounts of
weight loss achieved.
The secondary outcomes to be measured at the time
points of 6 months, 12 months, 24 months, 5 years and
10 years are as follows:
 Weight loss (%EWL, %TWL)
 Complications (any complication requiring any
intervention or a prolonged hospital stay or
additional outpatient visits)
 Perioperative factors (operation time, hospital stay,
nausea, ability to take fluids and mobilization)
 Remission of comorbidities (including, for example,
T2DM, hypertension, nonalcoholic fatty liver
disease); remission is defined as normalization of
measured values without medication
 Changes in nutritional, metabolic and safety
laboratory parameters (e.g., hemoglobin, vitamins,
albumin, electrolytes, liver enzymes, lipids)
 Glucose tolerance and insulin response during an
oral glucose tolerance test (OGTT) or meal test
 Continuous glucose monitoring (CGM)
 Changes in body composition (whole body fat with
dual-energy x-ray absorptiometry (DEXA) and
bioelectrical impedance (BIA), lean mass (DEXA
and BIA), bone mineral mass and density (DEXA),
subcutaneous fat (magnetic resonance imaging
(MRI)), intra-abdominal fat (MRI), liver fat
(magnetic resonance spectroscopy (MRS))
 Bile reflux at 6 months (for the OAGB group at
Helsinki University Hospital (HUH))
 Tendency for urolithiasis
 Changes in cortisol and other hormone metabolism
 Changes in blood and tissue (adipose tissue, muscle)
transcriptomics, proteomics, metabolomics
 Changes in tissue (adipose tissue, muscle)
mitochondrial activities
 Changes in gut and saliva microbiota and bile acid
metabolism
 Changes in quality of life and lifestyle and
gastrointestinal symptoms
Drop-out and lost-to-follow-up patients will be in-
cluded in the analyses with measurements and values
that have been obtained prior to drop-out. A 10% drop-
out rate has been included in the power calculation
regarding the primary outcome. Patients are regarded as
part of their original treatment group according to
randomization on an intention-to-treat basis.
An interim analysis regarding safety and trial progres-
sion has been performed after half of the patients have
been randomized and undergone surgery.
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Sample size
This study is designed as a superiority trial based on pre-
vious cohort series. According to power calculations
finding a difference of 10 in %EWL with the assump-
tions of mean %EWL = 60 (standard deviation (SD) =
17) in the RYGB group, with alpha = 0.05, 50 patients in
each group would be sufficient to reach the power of
80%. If a drop-out of 10% is taken into account, this
would mean 55 patients per group. Power calculations
were performed by simulation using the Mann-Whitney-
Wilcoxon test (PASS v13.0, NCSS Inc., Kaysville, Utah,
USA). Since there was a lack of published data on com-
parisons between these two operations at the time of
designing the study, we decided to recruit 60 patients for
both treatment groups in order to have sufficient
statistical power regarding the primary end point (10%
difference in %EWL at 2 years between the groups).
Inclusion criteria
Inclusion criteria were:
 Age >18 years
 BMI ≥35 kg/m2
 Eligible for gastric bypass surgery according to
national treatment guidelines
 Willingness to participate in this trial
Exclusion criteria
Exclusion criteria were:
 Anemia (hemoglobin <120 g/l)
 Pregnancy or lactation
 For MRI/MRS imaging: metal objects in the body or
claustrophobia
 Endoscopic evidence of hiatal hernia, reflux
esophagitis or Barret’s esophagus
 Any other condition that, in the opinion of the
investigator, could create a hazard for the safety of
the participant, endanger the study procedures or
interfere with the interpretation of study results
 Lack of consent
Study sites and randomization
The trial is being carried out in two academic centers:
HUH in collaboration with the University of Helsinki, and
Oulu University Hospital (OUH). Both bariatric centers
(HUH and OUH) are university hospitals that are tertiary
referral bariatric centers with a catchment area of around
one million people in Finland. Metabolic studies for pa-
tients in HUH are conducted by the Research Program for
Clinical and Molecular Metabolism, University of Helsinki.
The trial is carried out according to the Consolidated
Standards of Reporting Trials (CONSORT) statement.
The trial schedule is shown in Fig. 1. Surgeons
performing the intervention recruit eligible patients at a
preoperative visit (study baseline) and randomize them
according to protocol. This is an open-label study and
the patients and surgeons are informed of the
randomization outcome. Outcome analyses are also per-
formed without blinding. Randomization is carried out
as follows: 120 sheets of paper stating either “Single
Anastomosis Gastric Bypass” or “Roux-en-Y Gastric By-
pass” are divided into groups of four and six containing
equal numbers of both outcomes and then sealed into
opaque envelopes. These groups of opaque envelopes
are distributed to both centers (80 envelopes for HUH
and 40 envelopes for OUH) and then divided into two
batches (for patients with diabetes and those without).
The goal of this allocation sequence is to have equal
numbers of patients in both groups at both centers and
also an equal number of patients with diabetes in both
groups at both centers.
Interventions
When our current randomized study was designed there
was no consensus regarding the name for the OAGB
procedure in the bariatric surgery community. Hence,
we then decided to use the name SAGB and we named
the trial RYSA (Roux-en-Y Gastric Bypass vs Single-
Anastomosis Gastric Bypass).
Roux-en-Y gastric bypass
After insufflation with CO2 reaching 15mmHg intra-
abdominal pressure, a standard four-port laparoscopy
with a subxiphoidal liver retractor in place is carried out.
Biopsies of subcutaneous fat, the omentum and liver are
taken (at HUH). At 5 cm below the gastroesophageal
junction, an approximate 20- to 40-ml small pouch is
created with linear staplers. The omentum is divided
and an antecolic 80-cm BP limb is measured with a
marked dissector and anastomosed end-to-side with a
linear 45-mm stapler and the anterior defect is sutured
in two layers with a braided absorbable 2–0 running su-
ture. A 130-cm alimentary limb is measured with a
marked dissector and enteroanastomosis is created with
a 60-mm or 45-mm (at the HUH and OUH, respect-
ively) linear stapler and the remaining anterior defect is
sutured in one layer with a braded absorbable 2–0 run-
ning suture. The ends of both anastomotic staple lines
are secured with an extra stich. The connection between
the anastomoses is divided with two linear staplers and a
biopsy of the small bowel is obtained between the staple
lines (at HUH). The mesenteric defect and Petersen’s
space are closed with titanium clips or a slowly (180
days) absorbable barbed running suture (at the HUH
and OUH, respectively) (Fig. 2).
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One-anastomosis gastric bypass
After insufflation with CO2 reaching 15mmHg intra-
abdominal pressure, a standard four-port laparoscopy
with a subxiphoidal liver retractor in place is carried out.
Biopsies of subcutaneous fat, the omentum and liver are
taken (at HUH). A long gastric pouch is created with
linear staplers starting horizontally at the crow’s foot
and continuing towards the angle of this along a 38-Fr
bougie. An antecolic 210-cm BP limb is measured with a
marked dissector and anastomosed with a linear 45-mm
stapler side-to-side with the distal end of the pouch. The
remaining defect is sutured in two layers with a braided
Fig. 1 Trial schedule. DEXA dual-energy x-ray absorptiometry, ECG electrocardiogram, LA Los Angeles (classification), MRI magnetic resonance
imaging, SAGB single-anastomosis gastric bypass, V visit
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absorbable 2–0 running suture beginning and ending 2
cm proximal to the stapled anastomosis, thus securing
the BP limb’s position parallel to the pouch (Fig. 3).
We chose to do a 210-cm BP limb in OAGB and 80-
cm (BP) and 130-cm (alimentary) limbs in RYGB to ob-
tain equally long bypassed intestine in both groups.
Inpatient follow-up
After the operation all patients are monitored for 2 h in
the operation unit and then transferred to the ward,
where blood pressure, pulse, heart rate, temperature,
and blood glucose are measured and documented to-
gether with pain, nausea and fluid intake. Patients are
mobilized and fluids are given as soon as possible. Pa-
tients are discharged on the first or second postoperative
day if there are no abnormal symptoms or suspicion of
complications (elevated heart rate, fever, pain, nausea,
vomiting, low hemoglobin). Fluid intake must be at least
1000 ml/day and the patient must be sufficiently mobi-
lized and feel fit to go home. All patients are prescribed
multivitamins (Multivita Plus®) once a day, calcium car-
bonate and vitamin D 1000mg + 20 IU/day, and vitamin
B12 1mg/day. Women of fertile age are also prescribed
iron substitution 100mg/day. Other prescriptions in-
clude a proton-pump inhibitor (pantoprazole 40 mg/day)
for 3 months (at HUH) and the antithrombotic agent
enoxaparin 40mg/day subcutaneously for 10 days. Para-
cetamol 1000mg three times a day, metamizole +
pitofenone 500/5 mg three times a day and tramadol 50
mg three times a day are prescribed for pain.
Preoperative work-up and outpatient follow-up
Helsinki University Hospital and Oulu University Hospital
At 8 weeks prior to the operation (the baseline of the
study), all patients are evaluated for eligibility for surgi-
cal treatment according to the Finnish guidelines for
management of obesity and local protocols by an endo-
crinologist, surgeon, dietitian and anesthesiologist. This
includes a thorough medical check-up with laboratory
tests, BIA, assessment of obstructive sleep apnea and a
gastroscopy. If the inclusion criteria are met and no ex-
clusion criteria are found, patients can be recruited to
this study. Written consent is received for all study
patients. Together with extensive blood tests, we
perform an OGTT to identify patients with impaired
glucose tolerance or T2DM. Preoperatively, all patients
also fill in questionnaires to assess diseases, medications,
lifestyle and quality of life.
At 1 month after the operation, postoperative recovery
and comorbidities are assessed together with blood tests
and BIA.
At 3 months all patients meet with an internist or
endocrinologist, and nutritional, metabolic and safety
laboratory tests are evaluated and medications for
comorbidities are reviewed and optimized (at HUH). At
OUH, laboratory tests are analyzed, and patients are
contacted via telephone.
Fig. 2 Illustration of the Roux-en-Y gastric bypass technique
Fig. 3 Illustration of the one-anastomosis gastric bypass technique
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At 6 months a gastroscopy with comprehensive biop-
sies of the gastric tube, gastroesophageal junction and
esophagus as well as a radioisotope scanning for the de-
tection of bile reflux are performed (for the OAGB
group at HUH).
At 6 months,12 months, 24 months, 5 years and 10
years BIA measurement and OGTT are repeated accord-
ing to the same protocol as prior to the operation. Ac-
cordingly, nutritional, metabolic and safety laboratory
tests are again performed. All patients also fill in question-
naires and food diaries (at HUH). At OUH, all patients
meet an endocrinologist, and nutritional, metabolic and
safety laboratory tests are evaluated and medications for
comorbidities are reviewed and optimized.
University of Helsinki Obesity Research Unit
At 8 weeks before the operation, metabolic examinations
and a meal tolerance test are performed for all patients
at HUH. CGM is performed using the Abbott Freestyle
Libre device. Biopsies of subcutaneous fat, skin and a
muscle tissue (vastus lateralis muscle) are taken under
local anesthesia. Blood and diurnal urinary samples are
collected in order to analyze indicators of nutritional sta-
tus, metabolic and safety parameters, glucose tolerance,
cortisol and other hormone metabolism, bile acid metab-
olism, calcium homeostasis and a tendency for urolithia-
sis. Salivary bilirubin and microbiota and gut microbiota
are analyzed from saliva and feces samples, respectively.
Omics analyses are performed from blood and tissue
specimens and mitochondria-specific measurements
taken from tissue biopsies. DEXA and abdominal MRI
and MRS are used for analysis of the distribution of fat
tissue. The participants also fill out questionnaires and
diaries, and they are interviewed on health, symptoms,
lifestyle, and quality of life.
The exact same protocol is repeated for all patients at
HUH at 6 and 12months after the operation.
Body composition studies
Each participant’s weight, height, and waist and hip
circumference are measured and BMI and waist to hip
ratio are calculated. Body composition is analyzed by
BIA, DEXA, MRI, and proton MRS.
Bioelectrical impedance
The body water, body fat and amount of lean tissue are cal-
culated by measuring electrical impedance (Tanita MC-980).
DEXA
The bone mineral content, fat mass, and fat-free mass
are determined using a Lunar Prodigy whole-body
scanner (GE Medical Systems, Madison, WI).
MRI and MRS
Body fat distribution and liver fat content are analyzed
using MRI and MRS. The imaging and data analysis pro-
cedures have been described elsewhere [14].
Indirect calorimetry
Indirect calorimetry (Cosmed Q-NRG) is used to esti-
mate the basal metabolic rate from measurements of O2
consumption and CO2 production. This is measured
with the patient lying supine in bed and breathing
calmly and regularly in the canopy with a constant air
flow (to be adjusted to give O2 and CO2 concentrations
within the workable range).
Fasting blood samples
Routine laboratory tests, including a complete blood count,
and levels of vitamins, potassium, sodium, copper, selenium,
zinc, magnesium, calcium, lactate, creatine kinase, pyruvate,
creatinine, glycated hemoglobin A1c, cholesterol, low-density
lipoprotein cholesterol, high-density lipoprotein cholesterol
and triglycerides, plus a measure of thyroid function (with
thyroid-stimulating hormone), liver enzymes (aspartate
aminotransferase, alanine transferase, γ-glutamyltransferase,
alkaline phosphatase, bilirubin), and synthesis markers of the
liver (thromboplastin time, albumin) are taken. Lipoprotein
fractions are separated for measurement of chylomicrons,
high-density lipoprotein and low-density lipoprotein subspe-
cies. In addition, metabolic markers such as cytokines (e.g.,
high-sensitivity C-reactive protein), systemic global metabo-
lites (metabolomics, lipidomics, proteomics) and bile acids
are analyzed. Investigation of hemostasis activity, coagulation
parameters, platelet activity and function, as well as thrombin
formation capacity in platelet-free and platelet-rich plasma
are performed. Markers of chronic stress (e.g., copeptin, cor-
tisol, cortisol metabolites, aldosterone, renin, metanephrine,
normetanephrine) and calcium homeostasis (e.g., urate,
phosphorus, intact parathyroid hormone) are also measured.
MMT and OGTT
A mixed meal test (MMT) and OGTT are performed after
an overnight (10-h) fast. During the MMT the patients eat
a caloric-rich, partially liquid meal of 2620 kJ with a bal-
anced distribution of fat (24 g), carbohydrates (76 g) and
protein (24 g) (Resource® 2.5 Compact, Nestle Health
Science). A fasting blood sample is collected before inges-
tion of the meal, and postmeal samples are collected at 15,
30, 60, 120, 180, 240 and 360min for measurement of glu-
cose, insulin, c-peptide, incretins, lipids and lipoproteins,
appetite-regulating hormones and metabolites.
Additionally, a standard OGTT is performed with
similar measurements as in the MMT. A fasting blood
sample is collected after which patients take a 75-g oral
glucose dose. Postglucose time points for sample collec-
tion are 0, 30, 60, 120, and 180 min.
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Saliva, urine and fecal samples
Saliva is collected after stimulation by chewing parafilm.
Saliva samples are used for microbiota and metabo-
lomics analyses.
Urine is collected for 24 h in free-living conditions at
home. Urine samples are used to measure urinary
albumin, urea, creatinine, sodium, potassium and mag-
nesium, and for metabolomics analyses. Markers of
chronic stress (e.g., cortisol, cortisol metabolites, aldos-
terone, adrenalin metabolites) and calcium homeostasis
(e.g., calcium, citrate, urate, oxalate, phosphorus) are
measured. Furthermore, an additional urine sample is
collected on a study morning to perform a pregnancy
test for females of childbearing age.
Feces are collected either at the study center or at
home and stored at –80 °C within 24 h. Feces samples
are used for metagenome sequencing and fecal metabo-
lites, including fatty acid composition.
Fat, muscle and skin biopsy
A subcutaneous fat biopsy by liposuction (approximately
3 g) is taken under local anesthesia from the abdominal
area. One part of the sample is immediately frozen and
stored in liquid nitrogen or −80 °C until used for tran-
scriptional, protein or other biochemical analyses, and
another part is further prepared for isolation of adipo-
cytes and stroma vascular fraction (SVF) cells. Fat cell
size is determined from fresh adipocytes. Part of the SVF
is prepared for cell culture. Fat is also stored in paraffin
for future immunohistochemical analysis.
A needle muscle biopsy (~50mg) is taken under local
anesthesia and sterile conditions from the vastus lateralis
muscle with a Bergström needle. Part of the sample is
immediately frozen in liquid nitrogen after excision and
stored at –80 °C until used for transcriptional, protein or
other biochemical analyses. Other parts are prepared for
histological staining and electron microscopy and for
myoblast culture.
A skin biopsy (approximately 1 × 1 cm) is taken from
the abdomen before the fat biopsy. The biopsy specimen
is processed for a fibroblast culture.
Using the adipose tissue and muscle biopsies, and also
from the isolated SVF and myoblast cells, we perform a
comprehensive set of analyses measuring mitochondrial
biogenesis and function.
Induced pluripotent stem cells, leukocytes and other
blood cells
Leucocytes, preadipocytes, myoblasts and fibroblasts can
be used for the production of induced pluripotent stem
cells. Leukocytes and red blood cells are also extracted
and stored live for future analyses, and extraction of
DNA and RNA.
Genetic, epigenetic, transcriptomic analyses and other
omics analyses
DNA is isolated from a whole blood sample, tissue sam-
ples, feces and saliva. Genetic studies including genome-
wide scans and sequencing technologies are performed
to combine information obtained from genome-wide
transcriptomics analyses of target tissues (adipose, skin,
muscle, liver, gut, and so forth). Additionally, we will
measure the mitochondrial DNA copy number of the
tissues as an estimate of the mitochondrial amount.
RNA isolated from blood, adipose tissue, muscle, skin or
their cultures is used to study global tissue-specific RNA
profiles. Epigenetic profiling of the tissues may include
whole genome-scale methylation techniques.
Blood samples, tissue biopsies and urine samples are
used for other omics analyses such as metabolomics,
lipidomics and proteomics analyses. Saliva and fecal
samples are used for microbiota analyses.
Continuous glucose monitoring
CGM is carried out with the Freestyle Libre system (Ab-
bott). The sensor is applied on the back of the upper
arm and worn for 14 days per time point, during which
all patients keep a food diary for 3 days.
Hepatobiliary scintigraphy
Bile reflux is investigated with hepatobiliary scintigraphy
as described elsewhere [15]. Scintigraphy is performed
for all patient in the OAGB group of the HUH (40 patients)
6 months after the operation.
Endoscopic and histological assessment
All patients undergo a gastroscopy with biopsies from
the duodenum, antrum, corpus and gastroesophageal
junction as a part of preoperative assessment. During
the follow-up all OAGB patients at HUH are invited for
a gastroscopy 6 months after OAGB to assess endo-
scopic signs of reflux. Gastroscopies are performed with-
out sedation with a flexible endoscope (Olympus Q190,
Tokyo, Japan). Mucosal biopsies are obtained from the
jejunum, anastomosis, gastric pouch in 2-cm intervals,
cardia and esophagus. Biopsy specimen are prepared
with serial sections (5 μm thick) from formalin-fixed and
paraffin-embedded biopsy specimen after hematoxylin
and eosin and Alcian blue/periodic acid–Schiff staining.
Questionnaires and food diaries
All patients fill out questionnaires that extensively sur-
vey their quality of life, physical activity, social activity,
gastrointestinal symptoms, eating behavior, sleep, mental
state and general health status. A food diary is addition-
ally kept for 3 days to measure nutritional intake for
patients operated on at HUH.
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Ethical approval and informed consent
All procedures performed in studies involving human par-
ticipants are in accordance with the ethical standards of the
Institutional Research Committee and with the 1964
Helsinki Declaration and its later amendments or compar-
able ethical standards. The trial has been reviewed by
Helsinki University Hospital ethics committee (HUS/1706/
2016) and approved by the Helsinki University Hospital
Research Review Board (HUS269/2017). The trial is regis-
tered at www.clinicaltrials.gov (NCT02882685. Informed
consent was obtained from all individual participants.
Statistical analyses
Normally distributed variables will be expressed as the
mean and SD, and non-normally distributed variables
will be expressed as the median and interquartile range;
categorical variables will be expressed as the number
and percentage.
To test the group differences (OAGB vs RYGB) in the
primary and secondary endpoints, we will use the Stu-
dent’s t test for continuous normally distributed va-
riables, the Mann–Whitney U test for continuous non-
normally distributed data, and the chi-squared test or
Fisher’s exact test for categorical variables. Additionally,
we will conduct multivariable analysis with generalized
mixed linear regression or logistic regression models
with adjustment for possible confounding factors. The
statistical analyses will be conducted on an intention-
to-treat basis. A P value < 0.05 will be considered
statistically significant.
Interim results
According to our study design, we have made an interim
analysis half-way through recruitment to check that
there are no serious issues regarding safety according to
the Clavien–Dindo classification [16] or problems
regarding sample handling or data collection.
Between November 2016 and May 2018, 60 patients
(30 RYGB and 30 OAGB) were randomized and operated
on according to our study protocol.
Baseline BMI (given as median ± SD) was 44.0 ±
5.9 kg/m2 in the RYGB group and 44.9 ± 5.5 kg/m2 in
the OAGB group. There were 20 women in the RYGB
group and 21 in the OAGB group. The number of patients
with T2DM at baseline was 13 in the RYGB group and 11
in the OAGB group and the median ± SD T2DM duration
was 3.0 ± 5.9 years and 7.0 ± 4.9 years in the RYGB and
OAGB groups, respectively. Other baseline characteristics
are given in Table 1.
During the first 3 months of follow-up there have been
no deaths or reoperations in either group or the need
for admittance to the intensive care unit. In both groups
one patient has undergone additional gastroscopy due to
eating difficulties (Clavien–Dindo class IIIa). The patient
in the OAGB group had a normal esophagogastroscopy
finding but the patient in the RYGB group needed endo-
scopic dilatation of the gastroenteral anastomosis. One
patient in the RYGB group stayed one extra night on the
ward after the operation due to low hemoglobin, but no
transfusion or intervention was required (Clavien–Dindo
Class I). One patient in the RYGB group had an incisional
seroma (Clavien–Dindo class I). All other patients were
discharged on the first or second postoperative day.
There have not been any significant problems with
sample collection or data handling.
Conclusion
Obesity is a multifactorial disease and treatment needs
to be aimed at all aspects of the metabolic syndrome.
Ever since the early days of bariatric surgery there has
been enormous interest in finding out which is the opti-
mal procedure. Each operation has its pros and cons and
the definition of what is optimal is not clear. First, we
need to discover the true underlying mechanisms of
surgery-induced weight loss and remission of comorbidi-
ties and which of these mechanisms are related to a spe-
cific surgery and not just weight loss per se. Many
studies have shown the metabolic effects of bariatric sur-
gery and nowadays it is more appropriate to talk about
metabolic surgery. The comparison of RYGB with
OAGB has for a long time been a matter of opinion
since there have not been enough data from randomized
controlled trials, and both techniques have shown great
results [9].
Our current study takes on a comprehensive approach to
the entire concept of metabolic surgery and weight loss.
First, we are comparing RYGB and OAGB in a random-
ized controlled setting to find out whether there is a dif-
ference in weight loss, postoperative symptoms, adverse
effects, comorbidity remission and quality of life between
the procedures. We intend that any small differences
between these techniques will help us understand which
patient would benefit from a certain technique. Our study
protocol includes a thorough follow-up with regular
Table 1 Baseline characteristics
Female (% of
participants)
T2DM (% of
participants)
T2DM duration, years
(median ± SD)
HT (% of
participants)
Dyslipidemia (% of
participants)
OSA (% of
participants)
Arthrosis (% of
participants)
RYGB (n = 30) 20 13 3.0 ± 5.9) 18 8 12 16
OAGB (n = 30) 21 11 7.0 ± 4.9) 16 8 12 15
HT hypertension, OAGB one-anastomosis gastric bypass, OSA obstructive sleep apnea, RYGB Roux-en-Y gastric bypass, T2DM type 2 diabetes mellitus
Saarinen et al. Trials          (2019) 20:803 Page 8 of 10
outpatient visits including blood analyses, body compos-
ition measurements and questionnaires. Bile reflux is mea-
sured with a specific scintigraphic method which we have
previously tested in a pilot series [15]. In the current
study, the scan is prolonged to 90min to view the entire
potential bile exposure of the gastric tube and esophagus.
The risk of urolithiasis is analyzed from diurnal urine
samples, blood analyses and DEXA measurements.
Second, we want to discover the metabolic effects of
surgery and weight loss at a cellular level by measuring
changes in mitochondrial activity and the interplay
between gut hormones, bile acids, gut microbiota and
the regulation of glucose homeostasis. We use novel
analytic mechanisms for measuring energy expenditure
and mitochondrial activity. Gut hormone and bile acid
responses to meal stimulation are measured and glucose
homeostasis is studied with CGM and repeated OGTT
during the follow-up.
There might not be only one optimal metabolic sur-
gery technique and, once we understand what obesity
really is about at a cellular level and what changes are
needed and how they are met in order to reach goals of
obesity management, we can tailor our treatments to
each patient.
The trial is limited due to the small number of patients
and hence may be underpowered regarding some of the
secondary outcomes. A second limitation is that both
centers are more experienced in the RYGB technique,
which is likely to have an effect when comparing
operation duration. However, this should not interfere
with other outcomes.
Trial status
This trial protocol is version 6.3, 12 July 2015. According
to the interim analysis the trial can be completed safely.
Recruitment started on 13 September 2016 and is
estimated to be completed in November 2019.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-019-3898-y.
Additional file 1. SPIRIT 2013 checklist
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